Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The induction of immune tolerance to Fel d 1, the major cat allergen, involves modulating the immune response so that exposure no longer triggers an allergic reaction. Immunotherapeutic strategies include allergen immunotherapy (AIT) with adjuvants, peptide immunotherapy targeting T-cell epitopes, and novel delivery systems such as fusion proteins and virus-like particles. These approaches aim to re-educate the immune system, promoting regulatory T cell expansion and shifting the balance away from Th2-mediated allergic responses.
Modulating the immune response to Fel d 1 to induce tolerance and prevent allergic reactions. Strategies include promoting Treg cell expansion, shifting cytokine profiles, and engaging inhibitory receptors.
1 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Immune system (induction of immune tolerance to Fel d 1).